Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes

Accumulating evidence implicates innate immune activation in the pathobiology of myelodysplastic syndromes. A key myeloid-related inflammatory protein, S100A9, serves as a Toll-like receptor ligand regulating tumor necrosis factor-α and interleukin-1β production. The role of myelodysplastic syndrome-related inflammatory proteins in endogenous erythropoietin regulation and response to erythroid-stimulating agents or lenalidomide has not been investigated. The HepG2 hepatoma cell line was used to investigate in vitro erythropoietin elaboration. Serum samples collected from 311 patients with myelodysplastic syndrome were investigated (125 prior to treatment with erythroid-stimulating agents and 186 prior to lenalidomide therapy). Serum concentrations of S100A9, S100A8, tumor necrosis factor-α, interleukin-1β and erythropoietin were analyzed by enzyme-linked immunosorbent assay. Using erythropoietin-producing HepG2 cells, we show that S100A9, tumor necrosis factor-α and interleukin-1β suppress transcription and cellular elaboration of erythropoietin. Pre-incubation with lenalidomide significantly diminished suppression of erythropoietin production by S100A9 or tumor necrosis factor-α. Moreover, in peripheral blood mononuclear cells from patients with myelodysplastic syndromes, lenalidomide significantly reduced steady-state S100A9 generation (P=0.01) and lipopolysaccharide-induced tumor necrosis factor-α elaboration (P=0.002). Enzyme-linked immunosorbent assays of serum from 316 patients with non-del(5q) myelodysplastic syndromes demonstrated a significant inverse correlation between tumor necrosis factor-α and erythropoietin concentrations (P=0.006), and between S100A9 and erythropoietin (P=0.01). Moreover, baseline serum tumor necrosis factor-α concentration was significantly higher in responders to erythroid-stimulating agents (P=0.03), whereas lenalidomide responders had significantly lower tumor necrosis factor-α and higher S100A9 serum concentrations (P=0.03). These findings suggest that S100A9 and its nuclear factor-κB transcriptional target, tumor necrosis factor-α, directly suppress erythropoietin elaboration in myelodysplastic syndromes. These cytokines may serve as rational biomarkers of response to lenalidomide and erythroid-stimulating agent treatments. Therapeutic strategies that either neutralize or suppress S100A9 may improve erythropoiesis in patients with myelodysplastic syndromes.

[1]  F. Cantatore,et al.  Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis , 2017, International journal of immunopathology and pharmacology.

[2]  G. Mufti,et al.  Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Greenberg,et al.  Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta‐analysis , 2016, British journal of haematology.

[4]  A. Stamatoullas,et al.  Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion , 2016, Leukemia.

[5]  Michelle C. Chen,et al.  Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9 , 2016, Nature Medicine.

[6]  C. Hsiao,et al.  Toll-like receptor-4 is a target for suppression of proliferation and chemoresistance in HepG2 hepatoblastoma cells. , 2015, Cancer letters.

[7]  D. Starczynowski,et al.  Deconstructing innate immune signaling in myelodysplastic syndromes. , 2015, Experimental hematology.

[8]  A. Strongin,et al.  The Calcium-binding Proteins S100A8 and S100A9 Initiate the Early Inflammatory Program in Injured Peripheral Nerves* , 2015, The Journal of Biological Chemistry.

[9]  S. Colla,et al.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes , 2015, Leukemia.

[10]  Sheng Wei,et al.  The inflammatory microenvironment in MDS , 2015, Cellular and Molecular Life Sciences.

[11]  Sheng Wei,et al.  Induction of myelodysplasia by myeloid-derived suppressor cells. , 2013, The Journal of clinical investigation.

[12]  J. Simard,et al.  S100A8 and S100A9 Induce Cytokine Expression and Regulate the NLRP3 Inflammasome via ROS-Dependent Activation of NF-κB1 , 2013, PloS one.

[13]  T. Leanderson,et al.  Induction of nuclear factor‐κB responses by the S100A9 protein is Toll‐like receptor‐4‐dependent , 2012, Immunology.

[14]  Julie R. Boiko,et al.  Hematopoiesis sculpted by pathogens: Toll-like receptors and inflammatory mediators directly activate stem cells. , 2012, Cytokine.

[15]  R. Calado.  Immunologic aspects of hypoplastic myelodysplastic syndrome. , 2011, Seminars in oncology.

[16]  J. Cannon,et al.  Construction, expression, and purification of chimeric protein reagents based on immunoglobulin fc regions. , 2011, Methods in molecular biology.

[17]  C. Szczylik,et al.  The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. , 2010, Biochimica et biophysica acta.

[18]  M. Diederich,et al.  Pro-Inflammatory Cytokine-Mediated Anemia: Regarding Molecular Mechanisms of Erythropoiesis , 2010, Mediators of inflammation.

[19]  P. Valent.  Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports. , 2008, Leukemia research.

[20]  A. Raza,et al.  Immunomodulatory drugs in myelodysplastic syndromes , 2006, Expert opinion on investigational drugs.

[21]  M. Biffoni,et al.  Multiple Members of the TNF Superfamily Contribute to IFN-γ-Mediated Inhibition of Erythropoiesis1 , 2005, The Journal of Immunology.

[22]  A. List,et al.  Immunomodulatory Drugs , 2005, Cancer investigation.

[23]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[24]  W. Jelkmann,et al.  Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA‐2 and NF‐κB , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Carolyn L. Geczy,et al.  IFN-γ and TNF Regulate Macrophage Expression of the Chemotactic S100 Protein S100A81 , 2000, The Journal of Immunology.

[26]  K. Xu,et al.  IFN-gamma and TNF regulate macrophage expression of the chemotactic S100 protein S100A8. , 2000, Journal of immunology.

[27]  K. Zierold,et al.  The influence of nickel and cobalt on putative members of the oxygen-sensing pathway of erythropoietin-producing HepG2 cells. , 1998, European journal of biochemistry.

[28]  J. Price,et al.  Interferon γ Downregulates Stem Cell Factor and Erythropoietin Receptors But Not Insulin-Like Growth Factor-I Receptors in Human Erythroid Colony-Forming Cells , 1997 .

[29]  R. Stasi,et al.  Serum levels of tumour necrosis factor‐α predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome , 1997 .

[30]  R. Stasi,et al.  Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. , 1997, Clinical and laboratory haematology.

[31]  J. Price,et al.  Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. , 1997, Blood.

[32]  F. caligaris-Cappio,et al.  Anemia of chronic disorders in systemic autoimmune diseases. , 1997, Haematologica.

[33]  D. Lipschitz,et al.  Interferon‐γ exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development , 1995 .

[34]  P. Musto,et al.  Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin. , 1994, Haematologica.

[35]  M. Goldberg,et al.  Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. , 1992, Blood.

[36]  S. Zuckerman,et al.  Transcriptional and post-transcriptional mechanisms involved in the differential expression of LPS-induced IL-1 and TNF mRNA. , 1991, Immunology.